New Boston Scientific warning letter
This article was originally published in The Silver Sheet
Executive Summary
Boston Scientific failed to notify participants in a clinical trial of the risks associated with stent fractures, according to an FDA warning letter issued to the firm Aug. 30. An agency inspection conducted in May at Boston Scientific Cardiovascular found "serious violations" related to a clinical trial of a stent-graft for treating abdominal aortic aneurysms (AAA), a life-threatening condition that causes a weakening of the aorta. In April 2005 the company acquired TriVascular, a private firm that was developing less-invasive medical devices and procedures for treating AAA. The 43-patient, Phase I safety trial, initiated in 2003 by TriVascular, was halted in 2006 by Boston Scientific after researchers observed fractures in numerous stent-grafts. FDA's warning letter also notes that Boston Scientific did not evaluate two deaths that occurred during the study to determine if they were related to the device. The agency has requested that the firm "provide documentation of a corrective action plan that will ensure that all [unanticipated adverse device effects] observed in clinical studies sponsored by Boston Scientific will be appropriately evaluated and reported.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.